Tagged with B

Ipsen Farmaceutica BV Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are still relatively new to Ipsen, what has been the professional trajectory that has brought you to the head of this local affiliate? I came here…

ABIQUIFI In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the inequality decreases, so have barriers to purchasing medicines. Greater employment has clearly been an important factor, which also contributes via…

Abbott Hungary You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can you provide our readers with a better idea on the business environment as you took over the operations here? After…

Lundbeck Philippines You have been involved with Lundbeck since the beginning of its operations in the Philippines. How has the company evolved since you joined seven years ago to be where it stands now? I was contacted by the Lundbeck Regional Vice President in late 2002 and asked to come for an…

Bogin Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics industry, I would like to begin please with a brief history of Bogin. What was the market landscape in the…

Lloyd Laboratories Ms Balajadia, you founded Lloyd Laboratories in 1989. What was the driving force behind the establishment of the company? Truth is, when we started on our first business venture way back in 1976, we never even thought or planned of one day putting up a manufacturing plant. We were into…

Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…

Niaba The Netherlands is famous throughout Europe and the global pharmaceutical community for its research infrastructure – institutes, university hospitals, and public private partnerships. Given this foundation and the size of the country relative to larger biotech neighbors such as the UK, France, and Germany, how would you assess the strength…

Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…

Ferring BV Netherlands 2010 was a very important year for Ferring as it marks the 60th anniversary of the company’s founding. Amongst the various commemorations this year and in hearing the collective experiences of your general manager counterparts, what do you consider the main factors behind Ferring’s success over time? Perhaps the most…

Hizon Laboratories Hizon Laboratories has been present in the Philippines for more than a century and several generations of Hizon have been at the head of the company. How has the company evolved from its origins as a drugstore to where it stands today? Although my grandfather had a drugstore before putting…

Bagó Brazil Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic initiatives for specific sectors. I’m interested to know the point of view from Rio de Janeiro – what recommendations would…